Notably, FOXA1 is also independently prognostic of improved outcomes of patients with ER-positive disease as well as response to endocrine therapy, supporting an essential function of FOXA1 in luminal breast cancer [7,8,38]. Here, FOXA1 is linked to breast carcinoma.